Rare cancer patients get a voice in drug funding decisions
NCT ID NCT04814095
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 26 times
Summary
This study tracks 30 adults with rare cancers or rare genetic changes who are already taking a Health Canada-approved targeted therapy that isn't yet covered nationally. Researchers will measure how long patients live, their quality of life, and how well the treatment works. The goal is to gather real-world evidence to help decide if these therapies should be funded for wider use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BC Cancer
RECRUITINGVancouver, British Columbia, V5Z4E6, Canada
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.